特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性高シュウ酸尿症治療薬:パイプライン製品の分析

Primary Hyperoxaluria - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 474978
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
原発性高シュウ酸尿症治療薬:パイプライン製品の分析 Primary Hyperoxaluria - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 63 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、原発性高シュウ酸尿症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、休止中・中止されたプロジェクトなどに関する情報を最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

原発性高シュウ酸尿症 - 概要

原発性高シュウ酸尿症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 企業で開発中の製品

原発性高シュウ酸尿症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

原発性高シュウ酸尿症の治療薬開発に従事している企業

原発性高シュウ酸尿症 - 薬剤プロファイル

原発性高シュウ酸尿症 - 休止中のプロジェクト

原発性高シュウ酸尿症 - 開発が中止された製品

原発性高シュウ酸尿症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Table 1: Number of Products under Development for Primary Hyperoxaluria, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Products under Development by Companies, H2 2019
  • Table 4: Number of Products by Stage and Target, H2 2019
  • Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 6: Number of Products by Stage and Route of Administration, H2 2019
  • Table 7: Number of Products by Stage and Molecule Type, H2 2019
  • Table 8: Primary Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2019
  • Table 9: Primary Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2019
  • Table 10: Primary Hyperoxaluria - Pipeline by Amarna Therapeutics BV, H2 2019
  • Table 11: Primary Hyperoxaluria - Pipeline by BridgeBio Pharma Inc, H2 2019
  • Table 12: Primary Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2019
  • Table 13: Primary Hyperoxaluria - Pipeline by Intellia Therapeutics Inc, H2 2019
  • Table 14: Primary Hyperoxaluria - Pipeline by OxThera AB, H2 2019
  • Table 15: Primary Hyperoxaluria - Pipeline by Precision Biosciences Inc, H2 2019
  • Table 16: Primary Hyperoxaluria - Dormant Projects, H2 2019
  • Table 17: Primary Hyperoxaluria - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Primary Hyperoxaluria, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Targets, H2 2019
  • Figure 4: Number of Products by Stage and Targets, H2 2019
  • Figure 5: Number of Products by Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11520IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2019, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain and frequent urge to urinate. Treatment includes Oral preparations of phosphates and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 3, 1, 2 and 2 respectively.

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Hyperoxaluria - Overview
  • Primary Hyperoxaluria - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Primary Hyperoxaluria - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Hyperoxaluria - Companies Involved in Therapeutics Development
    • Allena Pharmaceuticals Inc
    • Alnylam Pharmaceuticals Inc
    • Amarna Therapeutics BV
    • BridgeBio Pharma Inc
    • Dicerna Pharmaceuticals Inc
    • Intellia Therapeutics Inc
    • OxThera AB
    • Precision Biosciences Inc
  • Primary Hyperoxaluria - Drug Profiles
    • AMA-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBP-711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCR-PHXC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit HAO1 for Primary Hyperaxuluria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit HAO1 for Primary Hyperoxaluria Type I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lumasiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oxabact - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reloxaliase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Hyperoxaluria - Dormant Projects
  • Primary Hyperoxaluria - Discontinued Products
  • Primary Hyperoxaluria - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer